
Merck’s $1.3 Billion Silence Deal: What Could Gene Silencing Treat?
Merck KGaA’s proposed $1.3 billion takeover of Silence Therapeutics puts two experimental medicines in focus. Divesiran aims to reduce repeated blood-removal procedures for a rare blood cancer. Zerlasiran targets lipoprotein(a), a largely inherited cardiovascular risk factor.
Understand how RNA gene silencing works, why it differs from DNA editing and what the clinical trials actually measured. This episode examines the promise of fewer procedures, the difference between lowering a blood marker and preventing heart attacks, and the evidence still needed before either medicine can be described…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.